TQ05105 tablets
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Chronic Graft Versus Host DiseaseGlucocorticoid-Refractory aGVHDModerate and High Risk MyelofibrosisMyelofibrosis
Phase 1
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
TerminatedNCT04941404
Start: 2022-06-10End: 2024-12-24Updated: 2026-06-03
To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects
CompletedNCT05982106
Start: 2021-07-19End: 2021-07-28Updated: 2023-08-08
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
CompletedNCT06024915
Start: 2023-09-21End: 2024-05-06Updated: 2025-12-12
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
RecruitingNCT06122831
Start: 2023-12-12End: 2027-04-30Target: 92Updated: 2025-12-08
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
TerminatedNCT06245941
Start: 2024-05-13End: 2025-12-30Updated: 2026-01-05
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
TerminatedNCT06388759
Start: 2022-08-01End: 2025-08-12Updated: 2025-08-29
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
Not yet recruitingNCT07608666
Start: 2026-07-01End: 2026-12-01Target: 17Updated: 2026-07-13
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Not yet recruitingNCT07708272
Start: 2026-07-01End: 2027-02-01Target: 60Updated: 2026-07-16
Phase 2
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
CompletedNCT05020652
Start: 2021-11-11End: 2023-12-26Updated: 2026-06-02
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
RecruitingNCT06300320
Start: 2024-05-07End: 2026-04-30Target: 52Updated: 2025-02-11